drugset / Trial / NCT06137742

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

NCT06137742 ↗

Phase 1/2 Active not recruiting 97 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH). Part A: An investigator- and participant-blind, sponsor-open, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics (PK) of PF-07868489 in healthy adult participants. Part B: A 24-week, randomized, double blind, placebo-controlled study to assess the safety, tolerability, PK, and pharmacodynamics (PD) of PF-07868489 in adult participants with PAH.

Timeline

Start
2023-11-17
Primary completion
2026-09-02
Completion
2026-09-02

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-07868489 Unknown — Subcutaneous